The Hold-Period Trap: Why Some Portfolio Companies Can't Exit
BDO's 2025 PE survey found 84% of fund managers dealing with extended hold periods. More than 4,000 US portfolio companies are past five years with no exit in sight. I'm not a PE operating partner. Inside the portfolio company, founders and revenue leaders are often handed a 100-day plan and told to accelerate revenue before anyone has diagnosed why it stalled.
What happens there is worth naming directly.
The 100-Day Plan Problem Is a Sequencing Problem
When a portfolio company struggles commercially, the cause is often structural: the plan came before the diagnosis. A new CRO gets hired. The org chart gets redrawn. Revenue targets get set. And the underlying confusion — who is actually the right customer, why the sales motion isn't repeatable, why the same objections keep killing deals — goes unexamined because the plan was already committed.
GTM Partners and Blue Ridge Partners both flag this in their 2025–2026 practitioner guides. I flag it because it recurs at the company level. The bottleneck isn't visible in the numbers until the hold period has already extended.
I can't tell you what it's like to sit in an LP review defending a portfolio. One level down, the problem is a revenue leader with no structured read on why the pipeline is soft. That leader still has to explain it to a board that expected different results.
Margin Without Revenue Legibility Is a Partial Answer
BCG's 100-Day Cost Reset positions AI-enabled zero-based redesign as the standard opening move for PE margin improvement. The margin math is real. But a portfolio company that has been optimized for cost and cannot demonstrate a repeatable, defensible sales motion still trades at a discount at exit. Buyers underwrite revenue quality — ICP clarity, customer base defensibility, sales motion repeatability — not just EBITDA.
Operating partners who treat cost and GTM as sequential — cost first, revenue second — leave multiple on the table. The companies that compound value during extended hold periods are the ones that instrument the commercial function early, not 18 months before exit.
The Concrete Moves That Actually Help
Run the diagnostic before the plan. ICP clarity, pipeline coverage, and positioning coherence are diagnosable in weeks. The 100-day plan should follow the diagnosis, not precede it. This is not complicated — it's just sequencing discipline that most plans skip.
Treat GTM instrumentation as a hold-period asset. Every quarter of structured commercial data is a quarter of evidence that compounds toward exit. Buyers underwrite trajectory. A company that can show 18 months of improving ICP clarity and pipeline quality tells a different story than one that can only show a snapshot.
Separate the cost reset from the revenue build — but run them in parallel. The operating partners who are navigating extended hold periods well are running both tracks simultaneously. Waiting on revenue until the cost work is done is a bet that the market will be forgiving. In the current environment, that bet is losing more often than it's winning.
A company with a clear commercial diagnostic can show why its revenue is real and repeatable — to its board, to buyers, to anyone who asks.
That's the job.